2. Search Result
Search Result
Results for "

PMNs

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

10

Peptides

4

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W016733
    D-Citrulline

    H-D-Cit-OH

    		 Endogenous Metabolite Cardiovascular Disease
    D-Citrulline (H-D-Cit-OH) is a stereoisomer of L-citrulline (HY-N0391). D-Citrulline significantly attenuates polymorphonuclear leukocyte (PMN)-induced cardiac contractile dysfunction in the isolated perfused rat heart subjected to ischemia/reperfusion via a non-NO-mediated mechanism .
    D-Citrulline
  • HY-119217
    AZ084
    2 Publications Verification

    		 CCR Inflammation/Immunology Endocrinology Cancer
    AZ084 is a potent, selective, allosteric and oral active CCR8 allosteric antagonist, with a Ki of 0.9 nM. Has potential to treat asthma . AZ084 restrains the formation of the immunologically tolerant pre-metastatic niche (PMN) and tumor cells metastasis in lung by downregulating Treg differentiation. AZ084 can be used in studies of asthma and cancer .
    AZ084
  • HY-12764
    6-OAU
    1 Publications Verification

    GTPL5846

    		 GPR84 ERK Bacterial Antibiotic Inflammation/Immunology
    6-OAU (GTPL5846) (6-n-octylaminouracil) is an GPR84 (G protein-coupled receptor 84) agonist, with an EC50 value of 105 nM. 6-OAU works as a chemoattractant to both PMNs and macrophages, and amplifies the proinflammatory cytokine IL-8, shows proinflammatory function. 6-OAU also displays anti-bacterial function .
    6-OAU
  • HY-P2606
    Antiflammin 2

    		Platelet-activating Factor Receptor (PAFR) Inflammation/Immunology
    Antiflammin 2 inhibits the synthesis of platelet-activating factor (PAF) with the IC50 of 100 nM .
    Antiflammin 2
  • HY-P2642
    Peptide 78

    		CXCR Inflammation/Immunology
    Peptide 78, a chemotactic cytokine, a 78 amino acid protein member of the IL-8 or C-X-C chemokine supergene family. ENA-78 plays an important role in the elicitation of predominantly neutrophils (PMNs) into the joints of rheumatoid arthritis (RA) .
    Peptide 78
  • HY-118261
    L 659286

    		Elastase Inflammation/Immunology
    L 659286 is an inhibitor of human polymorphonuclear leukocyte elastase (PMN elastase) (Ki=0.4 μM). Intratracheal injection of L 659286 can induce lung injury in hamsters.
    L 659286
  • HY-134123
    Lipoxin B4 methyl ester

    LXB4 methyl ester

    		 Drug Intermediate Leukotriene Receptor Metabolic Disease
    Lipoxin B4 (LXB4) methyl ester is a lipid soluble prodrug form of the transcellular metabolite LXB4. LXB4 is a positional isomer of LXA4 produced by the metabolism of 15-HETE or 15-HpETE by human leukocytes. At a concentration of 100 nM, LXB4 inhibits polymorphonuclear leukocyte (PMN) migration stimulated by leukotriene B4 (LTB4; Item No. 20110) and inhibits LTB4-induced adhesion of PMNs with an IC50 value of 0.3 nM.
    Lipoxin B4 methyl ester
  • HY-N2247A
    (+)-Guaiacin

    		Platelet-activating Factor Receptor (PAFR) Metabolic Disease
    (+)-Guaiacin is a compound extracted of the bark of Machilus wangchiana Chun. (Lauraceae). (+)-Guaiacin shows potent in vitro activities against the release of β-glucuronidase in rat polymorphonuclear leukocytes (PMNs) induced by platelet-activating factor (PAF) .
    (+)-Guaiacin
  • HY-P10738A
    N-Formyl-MMYALF TFA

    		Formyl Peptide Receptor (FPR) Infection
    N-Formyl-MMYALF TFA is a mitochondrial N-formyl peptide that has the activity of depleting calcium ions in the endoplasmic reticulum. N-Formyl-MMYALF TFA can inhibit the FPR-1-mediated chemotactic response of PMNs to bacterial peptides .
    N-Formyl-MMYALF TFA
  • HY-116444A
    16-HETE

    		Na+/K+ ATPase Cardiovascular Disease Inflammation/Immunology
    16-HETE is arachidonic acid metabolite through subterminal hydroxylation by cytochrome P-450. 16-HETE exhibits vasodilatory and PMN inhibitory effects and serves as biomarker for early stages of non-alcoholic fatty liver disease .
    16-HETE
  • HY-P0308
    [Glu1]-Fibrinopeptide B

    		Drug Intermediate Cardiovascular Disease
    [Glu1]-Fibrinopeptide B is derived from fibrinopeptide B amino acid residues 1-14. Human fibrinopeptide B (hFpB), a thrombin-derived proteolytic cleavage product of the fibrinogen B beta-chain, to stimulate neutrophils (PMN), monocytes, and fibroblasts.
    [Glu1]-Fibrinopeptide B
  • HY-P10738
    N-Formyl-MMYALF

    		Formyl Peptide Receptor (FPR) Infection
    N-Formyl-MMYALF is a potent mitochondrial N-formyl peptide (mtFP) that has the activity of depleting calcium ions in the endoplasmic reticulum. N-Formyl-MMYALF can inhibit the FPR-1-mediated chemotactic response of polymorphonuclear leukocytes (PMNs) to bacterial peptides .
    N-Formyl-MMYALF
  • HY-117811
    (R,R)-MK 287

    L-680574

    		 Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease
    (R,R)-MK 287 (L-680574) is a tetrahydrofuran derivative that potently inhibits the binding of [3H]C18-PAF to human platelets, polymorphonuclear leukocytes (PMNs), and lung membranes with Ki values of 6.1, 3.2, and 5.49 nM, respectively. (R,R)-MK 287 potently and selectively inhibits PAF-induced platelet aggregation (ED50=56 nM) and elastase release from PMNs (ED50=4.4 nM). (R,R)-MK 287 inhibits PAF-induced lethality in mice (ED50=0.8 mg/kg, po) and PAF-induced bronchospasm in guinea pigs (ED50=0.18 mg/kg) .
    (R,R)-MK 287
  • HY-148141
    JPE-1375
    2 Publications Verification

    		 Complement System Inflammation/Immunology
    JPE-1375 is a complement C5a receptor 1 (C5aR1) antagonist. JPE-1375 effectively inhibits polymorphonuclear leukocyte mobilization (EC50=6.9 µM) and reduces TNF levels (EC50=4.5 µM) in mice. JPE-1375 can be used in studies of autoimmune and inflammatory diseases .
    JPE-1375
  • HY-131651
    Leukotriene B4 ethanolamide

    LTB4 ethanolamide

    		 Endogenous Metabolite Leukotriene Receptor Cancer
    Leukotriene B4 ethanolamide (LTB4 ethanolamide) is an antagonist and a partial agonist for Leukotriene B4 (LTB4) receptor 1 (BLTR1). Leukotriene B4 ethanolamide ameliorates the tumor progression, which is only asscociated with inflammation .
    Leukotriene B4 ethanolamide
  • HY-125527A
    17(R)-Resolvin D1

    17(R)-RvD1; AT-RvD1

    		 TRP Channel Inflammation/Immunology
    17R-Resolvin D1 (17R-RvD1; AT-RvD1) is an aspirin-triggered epimer of Resolvin D1, which exhibits anti-inflammatory activity in mice and human PMNs cells . 17R-Resolvin D1 specificially inhibits TRPV3 with an IC50 of 398 nM and exhibits peripheral anti-nociceptive efficacy .
    17(R)-Resolvin D1
  • HY-106899A
    (rel)-MK 287

    (rel)-L-680573

    		 Platelet-activating Factor Receptor (PAFR) Others
    (rel)-MK 287 ((rel)-L-680573) is a relative configuration of MK 287. MK 287, a tetrahydrofuran analog, potently inhibited [ 3H]C18-PAF binding to human platelet, polymorphonuclear leukocyte (PMN) and lung membranes with Kis of 6.1 nM, 3.2 nM and 5.49 nM, respectively. MK 287 inhibits PAF-induced lethality in mice and PAF-induced bronchoconstriction in guinea pigs .
    (rel)-MK 287
  • HY-P1194
    Spantide I

    		Neurokinin Receptor Inflammation/Immunology
    Spantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation .
    Spantide I
  • HY-P1194A
    Spantide I TFA

    		Neurokinin Receptor Inflammation/Immunology
    Spantide I TFA, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation .
    Spantide I TFA
  • HY-N9975
    4'',5''-Dehydroisopsoralidin

    		β-glucuronidase Inflammation/Immunology Cancer
    4'',5''-Dehydroisopsoralidin is a β-glucuronidase inhibitor (IC50: 6.3 μM). 4'',5''-Dehydroisopsoralidin has anti-inflammatory and anti-oxidative effects. 4'',5''-Dehydroisopsoralidin can be used in the research of inflammation and cancners .
    4'',5''-Dehydroisopsoralidin
  • HY-174313
    Antibacterial agent 284

    		Bacterial Toll-like Receptor (TLR) Collagen Infection Inflammation/Immunology
    Antibacterial agent 284 (Compound 7) is an Antibacterial agent. Antibacterial agent 284 has a zinc-binding structure and potent inhibitory activity against Legionella pneumophila metalloprotease ProA (IC50: 0.96 μM) with zinc-binding structure. Antibacterial agent 284 significantly inactivates the cleavage of collagen IV and flagellin (ProA substrates) and reduces immune evasion from the TLR5-NF-κB pathway and PMN-mediated inflammation in human lung tissue explants. Antibacterial agent 284 is promising for Legionnaires' disease research .
    Antibacterial agent 284
  • HY-P0172A
    ATI-2341 TFA
    2 Publications Verification

    		 CXCR Inflammation/Immunology Endocrinology Cancer
    ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .
    ATI-2341 TFA
  • HY-P0172
    ATI-2341

    		CXCR Inflammation/Immunology Endocrinology Cancer
    ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .
    ATI-2341
  • HY-12927
    SX-517

    		CXCR Inflammation/Immunology
    SX-517 is a dual CXCR2/1 antagonist, containing boronic acid. SX-517 inhibits CXCL1-induced Ca 2+ flux (IC50=38 nM), and antagonizes CXCL8-induced [(35)S]GTPγS binding (IC50=60 nM) and ERK1/2 phosphorylation. SX-517 has significant ability for inflammation suppression, in both humanized polymorphonuclear (PMN) cells and in murine model .
    SX-517
  • HY-114041
    Resolvin E1
    2 Publications Verification

    RvE1

    		 Endogenous Metabolite Inflammation/Immunology
    Resolvin E1 (RvE1), a potent endogenous pro-resolving mediator of inflammation, is derived from omega-3 fatty acid eicosapentaenoic acid (EPA). Resolvin E1 is endogenously biosynthesized from EPA in the presence of Aspirin during the spontaneous resolution phase of acute inflammation, where specific cell-cell interactions occur. Resolvin E1 possesses unique counterregulatory actions that inhibit polymorphonuclear leukocyte (PMN) transendothelial migration. Resolvin E1 also acts as a potent inhibitor of leukocyte infiltration, dendritic cell migration, and IL-12 production .
    Resolvin E1
  • HY-125527AS
    17(R)-Resolvin D1-d5

    17(R)-RvD1-d5; AT-RvD1-d5

    		 Isotope-Labeled Compounds TRP Channel Inflammation/Immunology
    17(R)-Resolvin D1-d5 (17(R)-RvD1-d5) is deuterium labeled 17(R)-Resolvin D1. 17R-Resolvin D1 (17R-RvD1; AT-RvD1) is an aspirin-triggered epimer of Resolvin D1, which exhibits anti-inflammatory activity in mice and human PMNs cells . 17R-Resolvin D1 specificially inhibits TRPV3 with an IC50 of 398 nM and exhibits peripheral anti-nociceptive efficacy .
    17(R)-Resolvin D1-d5
  • HY-114041S1
    Resolvin E1-d4-1

    RvE1-d4-1

    		 Isotope-Labeled Compounds Endogenous Metabolite Inflammation/Immunology
    Resolvin E1-d4-1 is the deuterium labeled Resolvin E1. Resolvin E1 (RvE1), a potent endogenous pro-resolving mediator of inflammation, is derived from omega-3 fatty acid eicosapentaenoic acid (EPA). Resolvin E1 is endogenously biosynthesized from EPA in the presence of Aspirin during the spontaneous resolution phase of acute inflammation, where specific cell-cell interactions occur. Resolvin E1 possesses unique counterregulatory actions that inhibit polymorphonuclear leukocyte (PMN) transendothelial migration. Resolvin E1 also acts as a potent inhibitor of leukocyte infiltration, dendritic cell migration, and IL-12 production .
    Resolvin E1-d4-1
  • HY-114041S
    Resolvin E1-d4

    RvE1-d4

    		 Isotope-Labeled Compounds Endogenous Metabolite Inflammation/Immunology
    Resolvin E1-d4 (RvE1-d4) is deuterium labeled Resolvin E1. Resolvin E1 (RvE1), a potent endogenous pro-resolving mediator of inflammation, is derived from omega-3 fatty acid eicosapentaenoic acid (EPA). Resolvin E1 is endogenously biosynthesized from EPA in the presence of Aspirin during the spontaneous resolution phase of acute inflammation, where specific cell-cell interactions occur. Resolvin E1 possesses unique counterregulatory actions that inhibit polymorphonuclear leukocyte (PMN) transendothelial migration. Resolvin E1 also acts as a potent inhibitor of leukocyte infiltration, dendritic cell migration, and IL-12 production .
    Resolvin E1-d4
  • HY-19519
    Ladarixin
    1 Publications Verification

    DF 2156A free base

    		 CXCR Inflammation/Immunology Cancer
    Ladarixin (DF 2156A free base) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin can be used for the research of COPD and asthma .
    Ladarixin
  • HY-19519A
    Ladarixin sodium
    1 Publications Verification

    DF 2156A

    		 CXCR Infection Inflammation/Immunology Cancer
    Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthma .
    Ladarixin sodium
  • HY-W020790
    Sialyl-Lewis X

    sLeX

    		 Endogenous Metabolite Inflammation/Immunology
    Sialyl-Lewis X (sLeX) is a sialylated fucosylated tetrasaccharide, an endogenous antigen. Sialyl-Lewis X is a high-affinity ligand for selectins (E-, P-, and L-selectin) . Sialyl-Lewis X binds to ELAM-1 and CD62 and has the ability?to inhibits CD62-mediated neutrophil recruitment to sites of inflammation .
    Sialyl-Lewis X
  • HY-125516
    MCTR3

    		Endogenous Metabolite Others Inflammation/Immunology
    MCTR3 is a potent cytokine of pro-resolving mediating maresin conjugates in tissue regeneration (MCTR), which reduces the inflammatory response and promotes the tissue regeneration. MCTR3 exhibits potency in ameliorating LPS-induced acute lung injury and arthritis .
    MCTR3
  • HY-12764R
    6-OAU (Standard)

    GTPL5846 (Standard)

    		 Reference Standards GPR84 ERK Bacterial Antibiotic Inflammation/Immunology
    Prochloraz manganese (Standard) is the analytical standard of Prochloraz manganese. This product is intended for research and analytical applications. Prochloraz manganese is an antifungal agent, and is used in agricultural industries .
    6-OAU (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: